EO Launches Its Next Generation Cannabinoid Care Platform

New scalable, digital health offering makes personalized, clinically responsible cannabinoid guidance accessible to all older adults, adults in cancer treatment and cancer survivors.

‍

The platform was designed and tested with patients and clinicians at leading hospitals and NCI-Designated Cancer Centers.

‍

Boston, MA – October 2, 2025 – EO Care, Inc., the leader in cannabinoid-based symptom management, today announced the launch of the next generation of its cannabinoid care platform. For the first time, older adults seeking relief for pain, stress and sleep issues and those who are seeking relief for cancer-related symptoms will have free access to EO’s clinically responsible and personalized product, dose and use guidance recommendations.

‍

Cannabinoids have entered the mainstream of symptom management. Data shows that 17% of primary care patients, 21% of Americans over the age of 50, and up to 40% of those in cancer treatment use cannabis regularly for symptom management purposes, but a lack of guidance and oversight can lead to significant health risks and suboptimal outcomes.

‍

“For many older adults and people living with chronic conditions, medical cannabinoids offer meaningful symptom management and hope for a better quality of life, said Sean Collins, CEO and co-founder of EO. “Clinically appropriate, personalized guidance and purpose-designed products are fundamental drivers of safe, effective cannabinoid use. But to date, such guidance and products have been beyond the reach of the vast majority of adults for reasons of access and cost. As cannabinoids enter the medical mainstream and patients and providers seek direction and support on their use, EO is committed to providing expert care and optimal products to all who are seeking relief - as well as the cannabinoid efficacy and cost of care impact data that’s so critically needed by all healthcare stakeholders.”

‍

The platform’s HIPAA-compliant personalized product, dose and use recommendations are powered by a proprietary, adaptive Bayesian care engine. Recommendations are based on:

‍

• Patient guided inputs including symptoms, relevant aspects of their medical record, medications in use, and other care considerations.
• Clinical outcomes from thousands of anonymized patient interactions.
• A library of EO and 3rd-party peer reviewed studies.
• A unique medical cannabinoid ontology.
• Detailed clinical guidance and exclusion rules.

‍

Patients can also access free, ongoing messaging and phone support provided by EO’s clinician-trained team.

‍

All recommended products are sourced from EO’s extensive lineup of clinician-designed, hemp-derived Delta-9 THC products. All of these products are federally legal, organic, 3rd-party tested and produced in GMP-certified facilities.

‍

The free EO guidance platform and the company’s products are currently available at eo.care.

‍

About EO Care, Inc.

‍

EO is the leader in cannabinoid-based symptom management. The company provides personalized, clinically responsible care through its unique, scalable digital health platform and affordable, medicalized cannabinoid products. Board members, advisors and investors include Regina Benjamin, MD, MBA, former Surgeon General of the United States; Kristi Savacool, former CEO of AON Hewitt; and Bill Van Faasen, former CEO of Blue Cross Blue Shield Massachusetts. For more information, visit eo.care.

‍

Media Contact: EO Care Media Relations press@eo.care

‍

‍